MXPA06002668A - Agonista de a-2 no sedante de 1-(2,3-dimetil-fenil)-etil-1, 3-dihidro-imidazol-2-tiona. - Google Patents

Agonista de a-2 no sedante de 1-(2,3-dimetil-fenil)-etil-1, 3-dihidro-imidazol-2-tiona.

Info

Publication number
MXPA06002668A
MXPA06002668A MXPA06002668A MXPA06002668A MXPA06002668A MX PA06002668 A MXPA06002668 A MX PA06002668A MX PA06002668 A MXPA06002668 A MX PA06002668A MX PA06002668 A MXPA06002668 A MX PA06002668A MX PA06002668 A MXPA06002668 A MX PA06002668A
Authority
MX
Mexico
Prior art keywords
alpha
agonist
imizadole
nonsedating
thione
Prior art date
Application number
MXPA06002668A
Other languages
English (en)
Spanish (es)
Inventor
Todd M Heidelbaugh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MXPA06002668A publication Critical patent/MXPA06002668A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA06002668A 2003-09-12 2004-08-20 Agonista de a-2 no sedante de 1-(2,3-dimetil-fenil)-etil-1, 3-dihidro-imidazol-2-tiona. MXPA06002668A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50256203P 2003-09-12 2003-09-12
US10/891,953 US7141597B2 (en) 2003-09-12 2004-07-15 Nonsedating α-2 agonists
PCT/US2004/027134 WO2005034946A1 (fr) 2003-09-12 2004-08-20 Agoniste non sedatif $g(a)-2 1-(2, 3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadole-2-thione

Publications (1)

Publication Number Publication Date
MXPA06002668A true MXPA06002668A (es) 2006-06-06

Family

ID=34278841

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06002668A MXPA06002668A (es) 2003-09-12 2004-08-20 Agonista de a-2 no sedante de 1-(2,3-dimetil-fenil)-etil-1, 3-dihidro-imidazol-2-tiona.

Country Status (26)

Country Link
US (4) US7141597B2 (fr)
EP (2) EP1800679B1 (fr)
JP (1) JP4698591B2 (fr)
KR (1) KR101145046B1 (fr)
CN (1) CN100417379C (fr)
AT (2) ATE358479T1 (fr)
AU (1) AU2004279332B2 (fr)
BR (1) BRPI0413719A (fr)
CA (1) CA2537832C (fr)
CO (1) CO5680444A2 (fr)
CY (1) CY1107608T1 (fr)
DE (2) DE602004005720T2 (fr)
DK (2) DK1800679T3 (fr)
ES (1) ES2285522T3 (fr)
HK (2) HK1092704A1 (fr)
IL (1) IL173530A (fr)
MX (1) MXPA06002668A (fr)
NO (1) NO20060667L (fr)
NZ (1) NZ545181A (fr)
PL (2) PL1663206T3 (fr)
PT (1) PT1663206E (fr)
RU (1) RU2345987C2 (fr)
SI (1) SI1663206T1 (fr)
TW (1) TWI337999B (fr)
WO (1) WO2005034946A1 (fr)
ZA (1) ZA200601002B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
US7323485B2 (en) * 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) * 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20060293359A1 (en) * 2003-06-25 2006-12-28 Allergan, Inc. Methods and compositions for the treatment of diabetes
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
RU2383535C2 (ru) * 2004-09-24 2010-03-10 Аллерган, Инк. 4-(фенилметил и замещенный-фенилметил)-имидазол-2-тионы, действующие как специфические альфа2-адренергические агонисты
EP1791833A2 (fr) 2004-09-24 2007-06-06 Allergan, Inc. 4-(methyl cyclique condense)-imidazole-2-thiones utilises comme agonistes adrenergiques alpha2
BRPI0613077A2 (pt) * 2005-06-29 2010-12-21 Allergan Inc agonistas alfa-2 andrenérgicos para o tratamento de dor
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
EP2004143A2 (fr) * 2006-04-07 2008-12-24 Allergan, Inc. Compositions contenant des agents actifs relativement insolubles dans l'eau/non mouillables et procédés d'utilisation associés
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
AU2008256928A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
US8198315B2 (en) * 2007-05-23 2012-06-12 Allergan, Inc. Therapeutic substituted cyclic lactams
US20110028559A1 (en) * 2007-07-06 2011-02-03 Fang Wenkui K Substituted fluoroethyl ureas as alpha 2 adrenergic agents
JP5433576B2 (ja) * 2007-08-15 2014-03-05 アラーガン インコーポレイテッド アドレナリン作動化合物
WO2009023757A1 (fr) * 2007-08-15 2009-02-19 Allergan, Inc. Composés thérapeutiques
BRPI0816158A2 (pt) 2007-08-15 2017-06-13 Allergan Inc composto carbociclo fundido substituído com heterociclila e uso do mesmo.
WO2009052073A2 (fr) * 2007-10-18 2009-04-23 Allergan, Inc. Procédé de traitement de troubles sensorimoteurs avec des agonistes des récepteurs alpha-2 adrénergiques
US20110269805A1 (en) * 2007-10-18 2011-11-03 Gil Daniel W Method of treating sensorimotor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
EP2242748A1 (fr) * 2008-01-11 2010-10-27 Allergan, Inc. Composés thérapeutiques disulfure pour traiter la douleur et les diabètes
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
JP2012518005A (ja) 2009-02-13 2012-08-09 アラーガン インコーポレイテッド ４‐（１‐（３‐（ヒドロキシメチル）‐２‐メチルフェニル）エチル）‐１ｈ‐イミダゾール‐２（３ｈ）‐チオン
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
WO2020222188A1 (fr) 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Méthodes de traitement du prurit
CN110894508B (zh) * 2019-10-31 2021-08-06 内蒙古大学 一种调控白色脂肪棕色化的基因Adra1a的应用
US20230404979A1 (en) * 2020-10-26 2023-12-21 Rush University Medical Center Alpha-2 adrenergic receptor agonists to reduce mortality and improve outcomes in viral respiratory syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150266A (ja) * 1986-12-12 1988-06-22 Mitsui Petrochem Ind Ltd ベンジルイミダゾ−ル誘導体
ZA881807B (en) 1987-03-20 1988-09-05 Merrell Dow Pharmaceuticals Inc. Method for reducing reperfusion injury with imidazol-2-thiones
US4868197A (en) 1987-03-20 1989-09-19 Merrell Dow Pharmaceuticals Inc. Reducing reperfusion injury with 1,3-dihydro-4-methyl-5-(4-methylthio)benzoyl)-2H-imidazol-2-thione
US4798843A (en) * 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
EP0758323A1 (fr) 1994-05-02 1997-02-19 Zeneca Limited Composes heteroaryles herbicides a hydroxybenzyles substitues et derives
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists

Also Published As

Publication number Publication date
NO20060667L (no) 2006-04-06
KR20060119970A (ko) 2006-11-24
ATE358479T1 (de) 2007-04-15
PL379561A1 (pl) 2006-10-16
CN100417379C (zh) 2008-09-10
PT1663206E (pt) 2007-06-22
HK1092704A1 (en) 2007-02-16
EP1663206A1 (fr) 2006-06-07
AU2004279332A1 (en) 2005-04-21
WO2005034946A1 (fr) 2005-04-21
AU2004279332B2 (en) 2010-10-07
EP1800679B1 (fr) 2010-11-10
EP1800679A3 (fr) 2009-01-21
EP1663206B1 (fr) 2007-04-04
US8022226B2 (en) 2011-09-20
NZ545181A (en) 2009-07-31
TW200526591A (en) 2005-08-16
CO5680444A2 (es) 2006-09-29
IL173530A0 (en) 2006-07-05
US20080176918A1 (en) 2008-07-24
DK1663206T3 (da) 2007-07-30
JP4698591B2 (ja) 2011-06-08
CN1849118A (zh) 2006-10-18
JP2007505111A (ja) 2007-03-08
US7141597B2 (en) 2006-11-28
ATE487477T1 (de) 2010-11-15
DE602004030051D1 (de) 2010-12-23
TWI337999B (en) 2011-03-01
RU2006113600A (ru) 2007-11-10
ES2285522T3 (es) 2007-11-16
SI1663206T1 (sl) 2007-06-30
US7312238B2 (en) 2007-12-25
RU2345987C2 (ru) 2009-02-10
US20110034525A1 (en) 2011-02-10
DK1800679T3 (da) 2011-02-07
HK1104979A1 (en) 2008-02-01
DE602004005720T2 (de) 2007-12-27
DE602004005720D1 (de) 2007-05-16
IL173530A (en) 2010-05-31
US20070004790A1 (en) 2007-01-04
CY1107608T1 (el) 2013-03-13
ZA200601002B (en) 2007-04-25
PL1663206T3 (pl) 2007-08-31
EP1800679A2 (fr) 2007-06-27
US20050059721A1 (en) 2005-03-17
CA2537832A1 (fr) 2005-04-21
BRPI0413719A (pt) 2006-10-17
KR101145046B1 (ko) 2012-05-21
CA2537832C (fr) 2012-01-24

Similar Documents

Publication Publication Date Title
MXPA06002668A (es) Agonista de a-2 no sedante de 1-(2,3-dimetil-fenil)-etil-1, 3-dihidro-imidazol-2-tiona.
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
MXPA05009367A (es) Antagonistas del receptor opioide.
MY142444A (en) Chemokine receptor antagonists
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
HK1096399A1 (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-
WO2004082623A3 (fr) Composes piperidine substituee
AU2003239389A1 (en) Opioid receptor antagonists
TW200517106A (en) Sustained release pharmaceutical compositions
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера

Legal Events

Date Code Title Description
FG Grant or registration